Showing results (4991-5000 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|June 27, 2021
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential ToxicitiesLaura M Spring, Erika Nakajima, Jennifer Hutchinson, et al.
The Oncologist|June 22, 2021
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsDylan J Martini, Subir Goyal, Yuan Liu, et al.
The Oncologist|May 13, 2022
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal CancerThomas B Karasic, Timothy J Brown, Charles Schneider, et al.
The Oncologist|May 13, 2022
Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?Ralph Boccia, John Glaspy, Jeffrey Crawford, et al.
The Oncologist|May 31, 2022
Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and OutcomesRodrigo G Taboada, Rachel P Riechelmann, Carine Mauro, et al.
The Oncologist|May 31, 2022
Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal CancerChongkai Wang, Jaideep Sandhu, Marwan Fakih
The Oncologist|May 31, 2022
Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901)Wenying Peng, Liming Cao, Likun Chen, et al.
The Oncologist|May 31, 2022
Prospective Comparison of Geriatric Assessment and Provider's Assessment of Older Adults With Metastatic Breast Cancer in the CommunityRino S Seedor, Caitlin R Meeker, Bianca Lewis, et al.
The Oncologist|May 31, 2022
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141Maura L Gillison, George Blumenschein, Jerome Fayette, et al.
The Oncologist|May 31, 2022
Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I StudyThomas Ollila, James Butera, Pamela Egan, et al.
Pageof 571